INDOCO2023-10-012023-12-31 INDOCO2023-10-012023-12-31 INDOCO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses01Member INDOCO2023-10-012023-12-31in-bse-fin:OneOperatingExpenses02Member INDOCO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses01Member INDOCO2023-10-012023-12-31in-bse-fin:FourOperatingExpenses02Member INDOCO2023-12-31 INDOCO2023-10-012023-12-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2023-10-012023-12-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member INDOCO2023-10-012023-12-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member INDOCO2023-10-012023-12-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532612 INDOCO NOTLISTED Indoco Remedies Limited Equity 2023-04-01 2024-03-31 2024-01-23 2024-01-10 INR Lakhs Third quarter 11:00:00 12:15:00 2024-01-23 2024-01-23 Not applicable Single segment PHARMACEUTICALS 2023-10-01 2023-12-31 Unaudited Consolidated 4594200000.00 23500000.00 4617700000.00 1293000000.00 306200000.00 -176000000.00 899700000.00 100700000.00 243500000.00 1642300000.00 4309400000.00 308300000.00 -82000000.00 226300000.00 23000000.00 47700000.00 70700000.00 0.00 155600000.00 0.00 0.00 0.00 0.00 155600000.00 -1100000.00 154500000.00 163000000.00 -7400000.00 161900000.00 -7400000.00 184300000.00 2 1.69 1.69 0.00 0.00 1.69 1.69 1. The unaudited Consolidated Results for the quarter and Nine months ended 31-12-2023 have been reviewed by the Audit Committee and approved by the Board of Director of the Company at its meeting held on 23-01-2024. The Statutory Auditors have expressed an Unmodified Audit Opinion on these unaudited Consolidated Financial Results. 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. 3.The company has only one primary reportable segment of activity, namely, Pharmaceuticals. 4.Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: (Rs. in lakhs) Net Sales Qtr ended Qtr ended Qtr ended Nine mths Nine mths Year ended and Income 31.12.2023 30.09.2023 31.12.2022 ended ended 31.03.2023 from (Unaudited) (Unaudited) (Unaudited) 31.12.2023 31.12.2022 (Audited) Operations (Unaudited) (Unaudited) --------------------------------------------------------------------------------------------------------------------------------------- India 25,093 25,797 21,478 74,307 64,682 84,979 Outside India 20,782 21,561 19,637 60,607 56,449 79,026 -------------------------------------------------------------------------------------------------------------------------------------- Total : 45,875 47,358 41,115 1,34,914 1,21,131 1,64,005 =================================================================== 5. . The Consolidated Financial Results includes the Results of the following Companies ---------------------------------------------------------------------------------------------------------------------------------- Name of theCompany % of shareholding Consolidated as --------------------------------------------------------------------------------------------------------------------------------- Xtend Industrial Designers & Engineers Pvt Ltd 100.00 Subsidiary Indoco Remedies Czech SRO 100.00 Subsidiary Indoco Remedies UK Ltd 100.00 Subsidiary Warren Remedies Private Limited 100.00 Subsidiary FPP Holding Company , LLC 85.00 Subsidiary ================================================================= 6. The statutory auditors of the Company have carried out limited review of the financial results for the quarter ended 31st December, 2023. 7. (*) During the quarter the company has made payment amounting to Rs. 820 lakhs towards one time compensation to certain employees for their full & final settlement. Single segment 2023-04-01 2023-12-31 Unaudited Consolidated 13676500000.00 71900000.00 13748400000.00 3632100000.00 884900000.00 -333900000.00 2736300000.00 259700000.00 656400000.00 4802700000.00 12638200000.00 1110200000.00 -82000000.00 1028200000.00 225100000.00 53300000.00 278400000.00 0.00 749800000.00 0.00 0.00 0.00 0.00 749800000.00 -5500000.00 744300000.00 757700000.00 -7900000.00 752200000.00 -7900000.00 184300000.00 2 8.14 8.13 0.00 0.00 8.14 8.13 OTHER EXPENSES 1400600000.00 RESEARCH & DEVELOPMENT EXPENSES 241700000.00 OTHER EXPENSES 4064500000.00 RESEARCH & DEVELOPMENT EXPENSES 738200000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS -3000000.00 ITEMS THAT WILL NOT BE RECLASSIFIED TO PROFIT & LOSS -9000000.00 -3000000.00 -9000000.00 -800000.00 -2300000.00 ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS 1100000.00 ITEMS THAT MAY BE RECLASSIFIED TO PROFIT & LOSS 1200000.00 1100000.00 1200000.00 0.00 0.00